The evaluation and management of patients with neuroleptic malignant syndrome

Neurologic Clinics

Volumn 22, Issue 2, 2004, Pages 389-411

  Bhanushali, Minal J ^a   Tuite, Paul J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMPHETAMINE DERIVATIVE; ANTIEMETIC AGENT; APOMORPHINE; BROMOCRIPTINE; BUTYROPHENONE DERIVATIVE; CARBIDOPA; CITALOPRAM; CLOZAPINE; COCAINE; DANTROLENE; DIATRIZOATE; DROPERIDOL; ENTACAPONE; HALOPERIDOL; LEVODOPA; LITHIUM; LOXAPINE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PERGOLIDE; PHENOTHIAZINE DERIVATIVE; PROMETHAZINE; RESERPINE; TETRABENAZINE; TIOTIXENE; TOLCAPONE;

AKINESIA; AUTONOMIC DYSFUNCTION; BRADYKINESIA; CATATONIA; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DEHYDRATION; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; EVALUATION; HEAT STROKE; HUMAN; HYPERTHERMIA; HYPOTENSION; KIDNEY FAILURE; LABORATORY DIAGNOSIS; LIVER TOXICITY; MALIGNANT HYPERTHERMIA; MORTALITY; MUSCLE STIFFNESS; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; RECURRENT DISEASE; RESPIRATORY FAILURE; REVIEW; RISK FACTOR; SEROTONIN SYNDROME; SYMPTOMATOLOGY; THROMBOEMBOLISM;

ANTIPSYCHOTIC AGENTS; CATATONIA; DIAGNOSIS, DIFFERENTIAL; ELECTROCONVULSIVE THERAPY; HUMANS; MALIGNANT HYPERTHERMIA; MYOCARDIAL INFARCTION; NEUROLEPTIC MALIGNANT SYNDROME; SEROTONIN SYNDROME;

EID: 1642298049     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2003.12.006     Document Type: Review

References (84)

1. Delay J., Pichot P., Lempiere T., Blissalde B., Peigne F. Un neuroleptique majeur non phenothiazinique et non reserpinique, l'haloperidol, dans le traitmen des psychoses. (A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses) in French. Ann Med Psychol. 18:1960;145-152.
2. Caroff S., Mann S.C. Neuroleptic malignant syndrome. Med Clin North Am. 77:1993;185-202.
3. Heiman-Patterson T.D. Neuroleptic malignant syndrome and malignant hyperthermia. Important issues for the medical consultant. Med Clin North Am. 77:1993;477-492.
4. Reimer J., Kuhlmann A., Müller T. Neuroleptic malignant-like syndrome after rapid switch from bromocriptine to pergolide. Parkinsonism Relat Disord. 9:2002;115-116.
5. Gordon P.H., Frucht S.J. Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord. 6:2001;960.
6. Reeves R.R., Mack J.E., Torres R.A. Neuroleptic malignant syndrome during a change from haloperidol to risperidone. Ann Pharmacother. 35:2001;698-701.
7. Otani K., Mihara K., Okada M., Kaneko S., Fukushima Y. Crossover reaction between haloperidol and amoxapine for NMS. Br J Psychiatry. 159:1991;889.
8. Spivak B., Maline D.I., Vered Y., Kozyrev V.N., Mester R., Neduva S.A., et al. Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignant syndrome. Acta Psychiatr Scand. 102:2000;226-230.
9. Kubo S., Yoshiyuki O., Osamu K., Kazuya I., Ryoichi T., Ichiro N. An autopsy case of neuroleptic malignant syndrome (NMS) and its immunohistochemical findings of muscle-associated proteins and mitochondria. Forensic Science Int. 11:2001;155-158.
10. Adnet P., Lestavel P., Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 85:2000;129-135.
11. Sachdev P., Kruk J., Kneebone M., Kissane D. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol. 17:1995;233-234.
12. Kontaxakis V.P., Havaki-Kontaxaki B.J., Christodoulou N.G., Paplos K.G. Olanzapine-associated neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 26:2002;897-902.
13. Webster P., Wijeratne C. Risperidone-induced neuroleptic malignant syndrome. Lancet. 344:1994;1228-1229.
14. Raitasuo V., Vataja R., Elomaa E. Risperidone-induced neuroleptic malignant syndrome in young patient. Lancet. 344:1994;1705.
15. Duggal H.S. Neuroleptic malignant syndrome precipitated by promethazine and lorazepam. Aust N Z J Psychiatry. 35:2001;250-251.
16. Aydin N., Anaç E., Cayköylü A., Akçay F. Neuroleptic malignant syndrome due to citalopram overdose. Can J Psychiatry. 45:2000;941-942.
17. Gingrich J.A., Rudnick-Levin F., Almeida C., Innes L., Schneier H. Cocaine and catatonia. Am J Psychiatry. 155:1998;1629.
18. Chong L., Abbott P. Neuroleptic malignant syndrome secondary to loxapine. Br J Psychiatry. 159:1991;572-573.
19. Lasser E.C., Lamkin G.E. Effects of intrathecal injection of diatrizoate on dopamine receptors. Acad Radiol. 9:2002;826-829.
20. Coffey R.J., Edgar T.S., Francisco G.E., Graziani V., Meythaler J.M., Ridgely P.M., et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil. 83:2002;735-741.
21. Turner M., Gainsborough N. Neuroleptic malignant-like syndrome after abrupt withdrawal of baclofen. J Psychopharmacol. 15:2001;61-63.
22. Velamoor V. NMS complicated by diazepam. Br J Psychiatry. 160:1992;135-136.
23. Berardi D., Amore M., Keck P.J., Troia M., Dell'Atti M. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry. 44:1998;748-754.
24. Keck P.E. Jr., Pope H.G. Jr., Cohen B.M., McElroy S.L., Nierenberg A.A. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry. 46:1989;914-918.
25. Kontaxakis V.P., Havaki-Kontaxaki B.J., Stamouli S.S., Christodoulou G.N. Toxic interaction between risperidone and clozapine: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 26:2002;407-409.
26. Gill J., Singh H., Nugent K. Acute lithium intoxication and neuroleptic malignant syndrome. Pharmacotherapy. 23:2003;811-815.
27. Berardi D., Dell'Atti M., Amore M., De Ronchi D., Ferrari G. Clinical risk factors for neuroleptic malignant syndrome. Hum Psychopharmacol. 17:2002;99-102.
28. White D., Robins A. Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry. 158:1991;419-421.
29. Lee J.W. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry. 44:1998;499-507.
30. Pilo L. Neuroleptic malignant syndrome in organic brain disease and physical illness. Singapore Med J. 31:1990;311-313.
31. Caroff S., Mann S., McCarthy M., Naser J., Rynn M., Morrison M. Acute infectious encephalitis complicated by neuroleptic malignant syndrome. J Clin Psychopharmacol. 18:1998;349-351.
32. Otani K., Horiuchi M., Kondo T., Kaneko S., Fukushima Y. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry. 158:1991;850-853.
33. Suzuki A., Kondo T., Otani K., Mihara K., Yasui-Furukori N., Sano A., et al. Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome. Am J Pychiatry. 158:2001;1714-1716.
34. Gurrera R.J. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin Neuropharmacol. 25:2002;183-193.
35. Keck P.E.J., Pope H.G.J., Cohen B.M., McElroy S.L., Nierenberg A. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry. 46:1989;914-918.
36. Rosebush P., Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 146:1989;717-725.
37. Gurrera R. Diaphoresis and dehydration during neuroleptic malignant syndrome: preliminary findings. Psychiatry Res. 64:1996;137-145.
38. Kuno S., Mizuta E., Yamasaki S. NMS in Parkinson's patients:risk factors. Eur Neurol. 38:(Suppl 2):1997;56-59.
39. Ebadi M., Pfeiffer R.F., Murrin L.C. Pathogenesis and treatment of neuroleptic malignant syndrome. Gen Pharmacol. 21:1990;367-386.
40. Hermesh H., Manor I., Shiloh R., Aizenberg D., Benjamini Y., et al. High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. J Clin Psychopharmacol. 22:2002;252-256.
41. Addonizio G., Susman V.L., Roth S.D. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry. 143:1986;1587-1590.
42. Addonizio G., Susman V.L., Roth S.D. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry. 22:1987;1004-1020.
43. Velamoor V., Norman R., Caroff S., Mann S., Sullivan K., Antelo R. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 182:1994;168-173.
44. Neuroleptic malignant syndrome. Diagnostic and statistical manual of mental disorders. 4th edition:1994;739-742 American Psychiatric Association, Washington, DC.
45. Levenson J. Neuroleptic malignant syndrome. Am J Psychiatry. 142:1985;1137-1145.
46. Karagianis J., Phillips L., Hogan K., LeDrew K. Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother. 33:1999;623-630.
47. Védie C., Poinso F., Hemmi F., Rivet B. Major symptoms and differential diagnosis of neuroleptic malignant syndrome: three case reports. Eur Psychiatry. 15:2000;334-337.
48. Gurrera R., Romero J. Enzyme elevations in the neuroleptic malignant syndrome. Biol Psychiatry. 34:1993;634-640.
49. Blasi C., D'Amore F., Levati M., Bandinelli M. Neuroleptic malignant syndrome: a neurologic pathology of great interest for the internist. Ann Ital Med Int. 13:1998;111-116.
50. Young C., Kaufman B. Neuroleptic malignant syndrome postoperative onset due to levodopa withdrawal. J Clin Anesth. 7:1995;652-656.
51. Hopkins P. Malignant hyperthermia: advances in clinical management and diagnosis. Br J Anaesth. 85:2000;1118-1128.
52. Christian A., Ellis F., Halsall P. Is there a relationship between masseteric muscle spasm and malignant hyperpyrexia? Br J Anaesth. 62:1989;540-544.
53. Northoff G. Neuroleptic malignant syndrome and catatonia: one entity or two? Biol Psychiatry. 40:1996;431-433.
54. Northoff G., Krill W., Wenke J., Travers H., Pflug B. [The subjective experience in catatonia: systematic study of 24 catatonic patients]. Psychiatr Prax. 23:1996;69-73.
55. Mann S., Caroff S., Bleier H., Welz W., Kling M., Hayashida M. Lethal catatonia. Am J Psychiatry. 143:1986;1374-1381.
56. Lazarus A. Differentiating neuroleptic-related heatstroke from neuroleptic malignant syndrome. Psychosomatics. 30:1989;454-456.
57. Mills K. Serotonin syndrome. A clinical update. Crit Care Clin. 13:1997;763-783.
58. Carbone J.R. The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am. 18:2000;317-325.
59. Weiner A., Tilden F., McKay C.J. Serotonin syndrome: case report and review of the literature. Conn Med. 61:1997;717-721.
60. Caroff S., Rosenberg H. Data in case reports questioned. Clin Pharm. 3:1984;588-589.
61. Caroff S., Mann S., Keck P.J. Specific treatment of the neuroleptic malignant syndrome. Biol Psychiatry. 44:1998;378-381.
62. Goetz C., Blasucci L., Stebbins G. Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? Neurology. 52:1999;1227-1229.
63. Parry A., Ormerod L., Hamlin G., Saleem P. Recurrent sinus arrest in association with neuroleptic malignant syndrome. Br J Psychiatry. 164:1994;689-691.
64. Lappa A., Podestà M., Capelli O., Castagna A., Di Placido G., Alampi D. Successful treatment of a complicated case of neuroleptic malignant syndrome. ICU Med. 28:2002;976-977.
65. McCarron M., Boettger M., Peck J. A case of neuroleptic malignant syndrome successfully treated with amantadine. J Clin Psychiatry. 43:1982;381-382.
66. Colosimo C., Merello M., Albanese A. Clinical usefulness of apomorphine in movement disorders. Clin Neuropharmacol. 17:1994;243-259.
67. Nisijima K., Noguti M., Ishiguro T. Intravenous injection of levodopa is more effective than dantrolene as therapy for neuroleptic malignant syndrome. Biol Psychiatry. 41:1997;913-914.
68. Gregorakos L., Thomaides T., Stratouli S., Sakayanni E. The use of clonidine in the management of autonomic overactivity in neuroleptic malignant syndrome. Clin Auton Res. 10:2000;193-196.
69. Thomas P., Maron M., Rascle C., Cottencin O., Vaiva G., Goudemand M. Carbamazepine in the treatment of neuroleptic malignant syndrome. Biol Psychiatry. 43:1998;303-305.
70. Rosenberg M., Green M. Neuroleptic malignant syndrome. Review of response to therapy. Arch Intern Med. 149:1989;1927-1931.
71. Rosebush P., Stewart T., Mazurek M. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry. 159:1991;709-712.
72. Berardi D., Troia M., Veronesi L., Ferrari G. Neuroleptic malignant syndrome. Case reports. Minerva Psichiatr. 35:1994;199-219.
73. Susman V.L. Clinical management of neuroleptic malignant syndrome. Psychiatr Q. 72:2001;325-336.
74. Shalev A., Hermesh H., Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 50:1989;18-25.
75. Hermesh H., Aizenberg D., Weizman A. A successful electroconvulsive treatment of neuroleptic malignant syndrome. Acta Psychiatr Scand. 75:1987;237-239.
76. Nisijima K., Ishiguro T. Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases. J ECT. 15:1999;158-163.
77. Scheftner W., Shulman R. Treatment choice in neuroleptic malignant syndrome. Convuls Ther. 8:1992;267-279.
78. Caroff S., Mann S., Keck P.J., Francis A. Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol. 20:2000;257-259.
79. Trollor J., Sachdev P. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry. 33:1999;650-659.
80. van Agtmael M., van Harten P. [Malignant neuroleptic syndrome: complete anticoagulant treatment or not?]. Ned Tijdschr Geneeskd. 136:1992;1870-1872.
81. Lenler-Petersen P., Hansen B., Hasselstrom L. A rapidly progressing lethal case of neuroleptic malignant syndrome. Intensive Care Med. 16:1990;267-268.
82. Wells A., Sommi R., Crismon M. Neuroleptic rechallenge after neuroleptic malignant syndrome: case report and literature review. Drug Intell Clin Phar. 22:1988;475-480.
83. Susman V., Addonizio G. Recurrence of neuroleptic malignant syndrome. J Nerv Ment Dis. 176:1988;234-241.
84. Susman V., Addonizio G. Reinduction of neuroleptic malignant syndrome by lithium. J Clin Psychopharmacol. 7:1987;339-341.